What is BerGenBio ASA (BGBIO.OL)?

BerGenBio ASA (BGBIO.OL) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

BerGenBio ASA (BGBIO.OL)

Stock analysis · OSL · Healthcare · Biotechnology

Market Cap

N/A

PE (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

Beta

1.19

Day Range

N/A

52-wk Range

N/A

Avg Volume

N/A

Volume

N/A

BerGenBio ASA (BGBIO.OL) is a publicly traded company in the Healthcare sector. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 5 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

Earnings

Most Recent

Aug 20, 2025

EPS $-1.38 vs est. $-9.06

Beat by $7.68

Proprietary Signals

Signal snapshot temporarily unavailable.

About BerGenBio ASA

BerGenBio ASA is a biopharmaceutical firm in the clinical development stage, focused on developing therapies for drug-resistant, immune-evasive, and metastatic cancers, in addition to respiratory conditions. Its leading compound, Bemcentinib, is a bio-available small molecule AXL inhibitor currently in Phase II clinical trials for major cancer indications and COVID-19. The Phase II trial program specifically addresses non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Moreover, the company is progressing tilvestamab, an anti-AXL antibody, through Phase Ib clinical trials. BerGenBio ASA also maintains a collaboration agreement with Merck & Co. for its clinical studies. The company was founded in 2007 and operates from its base in Bergen, Norway.